Psycheceutical Bioscience

Executive Summary

Psycheceutical Bioscience is a private biotechnology company pioneering next-generation drug delivery technologies for psychedelic-based therapeutics. Its proprietary NeuroDirect™ platform enables topical, targeted delivery of neuroactive compounds directly to nerve tissue, bypassing systemic circulation to enhance safety and efficacy for mental health and pain disorders. Founded in 2019 and headquartered in Miami, the company focuses on addressing the limitations of current psychedelic therapies, such as off-target effects and poor bioavailability. While still preclinical, Psycheceutical's differentiated approach could capture value in the rapidly growing psychedelic drug delivery market. The company's low profile and lack of public disclosures suggest an early developmental stage, with potential partnerships or licensing deals as key value drivers.

Upcoming Catalysts (preview)

• Q3 2026Completion of NeuroDirect preclinical proof-of-concept study60% success
• Q4 2026First partnership or licensing agreement with a psychedelic drug developer40% success